MLchartDataset catalogue

Lutetium Lu 177-DOTA

Term · Oncology and biomedicine · MLC-T-ONC-014928

A radioconjugate composed of the chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) labeled with the beta-emitting isotope lutetium Lu 177 (Lu-177), that can be used for radioimmunotherapeutic purposes. Upon administration, Lu-177-DOTA may act as a hapten for pretargeted radioimmunotherapy, and delivers targeted beta radiation.

Table 1. Record
IdentifierMLC-T-ONC-014928
FieldOncology and biomedicine
Synonyms177Lu-DOTA; 177Lu-labeled DOTA; Lu-177-DOTA
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-014928",
  "term": "Lutetium Lu 177-DOTA",
  "field": "Oncology and biomedicine",
  "definition": "A radioconjugate composed of the chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) labeled with the beta-emitting isotope lutetium Lu 177 (Lu-177), that can be used for radioimmunotherapeutic purposes. Upon administration, Lu-177-DOTA may act as a hapten for pretargeted radioimmunotherapy, and delivers targeted beta radiation.",
  "synonyms": [
    "177Lu-DOTA",
    "177Lu-labeled DOTA",
    "Lu-177-DOTA"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-dota/"
}

Record 10,410 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.